NEW YORK (GenomeWeb) – Greenwood Genetic Center announced today that it has signed an agreement to use FDNA's Face2Gene next-generation phenotyping technology in order to gain insights into thousands of undiagnosed patients with rare diseases.

Face2Gene uses facial analysis, deep learning, and artificial intelligence to evaluate symptoms of patients with rare genetic diseases and suggest possible diagnoses based on a database of more than 10,000 rare disease syndromes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.